Floatz logo

Romidepsin

Estrogen Receptor-positive Breast Cancer

Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Estrogen Receptor-positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 2BB
Inno-206
Baylor Breast Care Center
Phase 2BB
FULVESTRANT
Olema Pharmaceuticals, Inc.
Phase 3BB
TRASTUZUMAB
Dana-Farber Cancer Institute
Phase 3BB

View all 30 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →